Description

An introductory diagram from a review on gut microbiota-targeted therapeutics for metabolic disorders. The figure illustrates the conceptual framework linking dysbiosis to obesity, type 2 diabetes, hyperlipidemia, and non-alcoholic fatty liver disease.

Figure 1

Diagram

Source Paper

Gut Microbiota-Targeted Therapeutics for Metabolic Disorders: Mechanistic Insights into the Synergy of Probiotic-Fermented Herbal Bioactives.

International journal of molecular sciences (2025)

PMID: 40564947

DOI: 10.3390/ijms26125486

Cite This Figure

![Figure 1: An introductory diagram from a review on gut microbiota-targeted therapeutics for metabolic disorders. The figure illustrates the conceptual framework linking dysbiosis to obesity, type 2 diabetes, hyperlipidemia, and non-alcoholic fatty liver disease.]()

> Source: Yue Fan et al. "Gut Microbiota-Targeted Therapeutics for Metabolic Disorders: Mechanistic Insigh." *International journal of molecular sciences*, 2025. PMID: [40564947](https://pubmed.ncbi.nlm.nih.gov/40564947/)

<figure>
  <img src="" alt="An introductory diagram from a review on gut microbiota-targeted therapeutics for metabolic disorders. The figure illustrates the conceptual framework linking dysbiosis to obesity, type 2 diabetes, hyperlipidemia, and non-alcoholic fatty liver disease." />
  <figcaption>Figure 1. An introductory diagram from a review on gut microbiota-targeted therapeutics for metabolic disorders. The figure illustrates the conceptual framework linking dysbiosis to obesity, type 2 diabetes, hyperlipidemia, and non-alcoholic fatty liver disease.<br>  Source: Yue Fan et al. "Gut Microbiota-Targeted Therapeutics for Metabolic Disorders: Mechanistic Insigh." <em>International journal of molecular sciences</em>, 2025. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40564947/">40564947</a></figcaption>
</figure>

Preuves associées

Berberine pour Gut Dysbiosis

Note D · 2 études